Palbociclib in combination with sunitinib exerts a synergistic anti-cancer effect in patient-derived xenograft models of various human cancers types

Moskovits, Neta; Peretz, Idit; Chausky, Eva; Itzhaki, Ella; Shmuel, Nofar; Meerson, Raisa; Tarasenko, Nataly; Kaufman, Aleksandr; Stemmer, Amos; Yaffe, Ranny; Bareket‐Samish, Avital; Edison, Natalia; Goldman, Tal; Stemmer, Salomon M.

doi:10.1016/j.canlet.2022.215665

Cited by 6 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several studies on the combination of Pal and Alp [59,62], and a clinical study involving this potentially synergistic combination is ongoing [63]. However, to our knowledge, this was the first study investigating this combination using a delivery system that targets the tumor (Pal in combination with other drugs encapsulated in a nanocarrier) [64]. The study provides preclinical in vivo PDX evidence which supports the continued evaluation of P(RGD)Pal,Alp NCs.…”

Section: Fluorescent Ncs Containing Synergistic Drugsmentioning

confidence: 62%

Proteinoid Polymers and Nanocapsules for Cancer Diagnostics, Therapy and Theranostics: In Vitro and In Vivo Studies

Itzhaki

Elias

Moskovits³

et al. 2023

JFB

Self Cite

View full text Add to dashboard Cite

Proteinoids—simple polymers composed of amino acids—were suggested decades ago by Fox and coworkers to form spontaneously by heat. These special polymers may self-assemble in micrometer structures called proteinoid microspheres, presented as the protocells of life on earth. Interest in proteinoids increased in recent years, in particular for nano-biomedicine. They were produced by stepwise polymerization of 3–4 amino acids. Proteinoids based on the RGD motif were prepared for targeting tumors. Nanocapsules form by heating proteinoids in an aqueous solution and slowly cooling to room temperature. Proteinoid polymers and nanocapsules suit many biomedical applications owing to their non-toxicity, biocompatibility and immune safety. Drugs and/or imaging reagents for cancer diagnostic, therapeutic and theranostic applications were encapsulated by dissolving them in aqueous proteinoid solutions. Here, recent in vitro and in vivo studies are reviewed.

show abstract

Section: Fluorescent Ncs Containing Synergistic Drugsmentioning

confidence: 62%

Proteinoid Polymers and Nanocapsules for Cancer Diagnostics, Therapy and Theranostics: In Vitro and In Vivo Studies

Itzhaki

Elias

Moskovits³

et al. 2023

JFB

Self Cite

View full text Add to dashboard Cite

show abstract

The role of targeting CDK4/6 in cancer immunotherapy

Sun,

Dong,

Wang

et al. 2024

Holist Integ Oncol

View full text Add to dashboard Cite

Cyclin-dependent kinase 4/6 (CDK4/6) acts as a crucial point of regulation in the G1-to-S transition in the cell division cycle, its aberrant activation was found in various human cancers, leading to abnormal cell proliferation. Recent clinical trials have reported that combined with other small-molecule targeted therapies, CDK4/6 inhibitors increase overall survival and objective response rates in breast cancer (BC), non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). Notably, targeting CDK4/6 triggers an antitumor immune response, providing a potential combined application method for immunotherapy. In this review, we summarize underlying mechanism of targeting CDK4/6 in regulating antigen presentation, immune cell activation, and tumor immune microenvironment (TIME) remodeling and in producing synergistic effects with immune checkpoint blockade (ICB) in cancer clinical treatment.

show abstract

PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma

Hu,

Cao,

et al. 2024

Cancer Letters

View full text Add to dashboard Cite

Palbociclib in combination with sunitinib exerts a synergistic anti-cancer effect in patient-derived xenograft models of various human cancers types

Cited by 6 publications

References 15 publications

Proteinoid Polymers and Nanocapsules for Cancer Diagnostics, Therapy and Theranostics: In Vitro and In Vivo Studies

Proteinoid Polymers and Nanocapsules for Cancer Diagnostics, Therapy and Theranostics: In Vitro and In Vivo Studies

The role of targeting CDK4/6 in cancer immunotherapy

PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma

Contact Info

Product

Resources

About